[AI Supercharges Fentanyl Production And Distribution, Study Finds](https://wbbsec.com/opinions-and-features/ai-supercharges-fentanyl-production-and-distribution-study-finds/)
[AI Supercharges Fentanyl Production And Distribution, Study Finds](https://wbbsec.com/opinions-and-features/ai-supercharges-fentanyl-production-and-distribution-study-finds/)

Our investment banking and equity research practices are concentrated in three primary areas of the life sciences including the biotechnology, specialty pharmaceuticals and medical devices sectors. The life sciences space is a large universe populated by thousands of companies operating in perilous environments. Life Science investing is a niche focus fraught with uncertainty and risk. Our competency is in analyzing and evaluating companies to distill the universe to the few meaningful opportunities that exist for our investors and clients based on our experience, historical performance and rigorous diligence processes.


The number of biotechnology companies operating in life sciences has surged over the last decade. At the same time, the market has become fractured as discoveries have created entirely new classes of biotechnology companies, such as the rise of new immunotherapy and regenerative medicine companies. With every week comes the public launch of a new biotechnology venture or the announcement of another breakthrough discovery requiring capital for commercialization. Our decades of experience in the life sciences domain has allowed us to cultivate an ability to discern biotechnology companies with exceptional science with meaningful markets, and we understand what the needs and expectations for performance are for these types of companies.

Specialty Pharmaceuticals

Specialty pharmaceutical companies are a class of pharmaceutical companies that operate in a very well defined therapeutic class or niche indication. Usually these companies research and develop drugs for specialty physicians that are intended for very uncommon diseases. The therapeutic classes these drugs target span oncology, virology, neurology, and orphan diseases for which the population of patients is sometimes incredibly small. Breakthroughs in this realm are occurring at a rapid pace, and with the rise of monoclonal antibodies and targeted therapies, the field will only become denser as traditional biotechnology products seek similar markets.

Medical Devices

Medical device companies now span an immense range of capabilities. From diagnostics to implantable bioelectronics and nanotechnology, the medical device field is an ever-expanding sector of the life sciences space that is providing meaningful differences to the lives of people around the world. The medical device market can be very difficult to assess, however, as impact of new technologies usually take a great deal of time. Device adoption is usually slower and has lower thresholds for success than other types of medical technologies in the life sciences for various market factors. Therefore having a team of experts who understand the nuances of the medical device fields is important to finding and investing in credible companies with the most compelling medical device technology.